Name | Lalistat 1 |
---|
Description | Lalistat 1 is a potent, selective, and competitive inhibitor of lysosomal acid lipase (LAL) and against purified human LAL (phLAL) with an IC50 of 68 nM. Lalistat 1 is a inhibitor of immunoglobulin A1 protease (IgA1P) proteases for H. influenzae, has less effects on other serine hydrolases (trypsin or β-lactamase, etc.). Lalistat 1 can be used for the research of niemann-pick type C (NPC) disease[2]. |
---|---|
Related Catalog | |
Target |
IC50: 68 nM ( human LAL)[1] |
In Vitro | Lalistat 1 (0-100 μM) shows activity against different non-typeable H. influenzae (NTHi) IgAP variants from clinical isolates in Elisa assay. It shows a dose-dependent inhibition of IgA1P B1 and B2, but at higher inhibitor concentrations, consistent with the higher expression levels of these variants. Nearly complete inhibition of IgA1P B1 and B2 is observed at 50 μM, with complete inhibition at 100 μM[1]. |
References |
Molecular Formula | C12H18N4O3S |
---|---|
Molecular Weight | 298.36 |
Hazard Codes | Xi |
---|